| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue and Organ Procurement | 113 | 2023 | 896 | 18.720 |
Why?
|
| Organ Transplantation | 61 | 2023 | 1139 | 10.040 |
Why?
|
| Tissue Donors | 95 | 2023 | 2240 | 8.900 |
Why?
|
| Living Donors | 55 | 2022 | 620 | 7.590 |
Why?
|
| Kidney Transplantation | 147 | 2021 | 4251 | 6.390 |
Why?
|
| Medical Tourism | 13 | 2018 | 57 | 3.540 |
Why?
|
| Death | 18 | 2023 | 678 | 2.620 |
Why?
|
| Donor Selection | 10 | 2019 | 201 | 1.880 |
Why?
|
| Waiting Lists | 31 | 2022 | 692 | 1.840 |
Why?
|
| International Cooperation | 13 | 2016 | 1420 | 1.790 |
Why?
|
| Brain Death | 12 | 2022 | 348 | 1.720 |
Why?
|
| Kidney Failure, Chronic | 19 | 2021 | 2538 | 1.490 |
Why?
|
| Transplantation | 8 | 2013 | 217 | 1.390 |
Why?
|
| Altruism | 6 | 2016 | 204 | 1.100 |
Why?
|
| Organ Preservation | 7 | 2023 | 331 | 1.090 |
Why?
|
| Gift Giving | 5 | 2016 | 80 | 1.080 |
Why?
|
| Health Policy | 12 | 2016 | 2661 | 1.070 |
Why?
|
| Transplants | 3 | 2022 | 209 | 1.020 |
Why?
|
| Commerce | 6 | 2014 | 592 | 0.990 |
Why?
|
| Government Regulation | 6 | 2011 | 522 | 0.920 |
Why?
|
| Kidney | 37 | 2019 | 7186 | 0.910 |
Why?
|
| Liver Transplantation | 26 | 2022 | 2119 | 0.870 |
Why?
|
| Kidney Diseases | 12 | 2018 | 2149 | 0.820 |
Why?
|
| Cadaver | 29 | 2011 | 1337 | 0.770 |
Why?
|
| Motivation | 12 | 2019 | 1971 | 0.770 |
Why?
|
| Travel | 5 | 2009 | 788 | 0.750 |
Why?
|
| Health Services Accessibility | 8 | 2015 | 5137 | 0.670 |
Why?
|
| Humans | 269 | 2023 | 744343 | 0.640 |
Why?
|
| Tissue and Organ Harvesting | 8 | 2019 | 369 | 0.640 |
Why?
|
| Histocompatibility Testing | 13 | 2019 | 741 | 0.620 |
Why?
|
| Blood Circulation | 1 | 2018 | 251 | 0.580 |
Why?
|
| Graft Survival | 34 | 2021 | 3737 | 0.570 |
Why?
|
| Pancreas Transplantation | 11 | 2006 | 187 | 0.560 |
Why?
|
| Directed Tissue Donation | 2 | 2006 | 19 | 0.560 |
Why?
|
| China | 7 | 2023 | 2248 | 0.550 |
Why?
|
| Registries | 11 | 2018 | 8089 | 0.550 |
Why?
|
| Models, Organizational | 4 | 2015 | 574 | 0.550 |
Why?
|
| Informed Consent | 10 | 2014 | 995 | 0.540 |
Why?
|
| Immunosuppressive Agents | 26 | 2019 | 4149 | 0.530 |
Why?
|
| Graft Rejection | 44 | 2006 | 4397 | 0.530 |
Why?
|
| World Health Organization | 8 | 2014 | 1318 | 0.530 |
Why?
|
| Shock | 1 | 2018 | 318 | 0.530 |
Why?
|
| Ethics, Medical | 6 | 2015 | 792 | 0.520 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2018 | 3923 | 0.510 |
Why?
|
| Needs Assessment | 2 | 2018 | 1147 | 0.500 |
Why?
|
| Facial Transplantation | 1 | 2016 | 226 | 0.470 |
Why?
|
| Government | 1 | 2014 | 165 | 0.450 |
Why?
|
| Social Values | 1 | 2014 | 224 | 0.450 |
Why?
|
| Ethics, Professional | 1 | 2013 | 102 | 0.440 |
Why?
|
| HLA Antigens | 16 | 2019 | 1381 | 0.430 |
Why?
|
| New England | 9 | 2016 | 1022 | 0.420 |
Why?
|
| Policy Making | 1 | 2016 | 554 | 0.420 |
Why?
|
| Health Services Needs and Demand | 4 | 2014 | 1411 | 0.420 |
Why?
|
| Transplantation, Homologous | 37 | 2019 | 4776 | 0.420 |
Why?
|
| Upper Extremity | 1 | 2016 | 648 | 0.400 |
Why?
|
| Government Agencies | 1 | 2011 | 156 | 0.390 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 1504 | 0.390 |
Why?
|
| Geography | 2 | 2012 | 669 | 0.390 |
Why?
|
| Nephrectomy | 5 | 2017 | 1050 | 0.380 |
Why?
|
| Social Responsibility | 2 | 2011 | 389 | 0.370 |
Why?
|
| Patient Selection | 13 | 2010 | 4215 | 0.340 |
Why?
|
| Tissue Transplantation | 2 | 2010 | 130 | 0.330 |
Why?
|
| Mycophenolic Acid | 6 | 2004 | 343 | 0.330 |
Why?
|
| Attitude of Health Personnel | 4 | 2018 | 3843 | 0.330 |
Why?
|
| Residence Characteristics | 1 | 2018 | 2050 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 10 | 2016 | 7279 | 0.320 |
Why?
|
| Tacrolimus | 6 | 2004 | 743 | 0.310 |
Why?
|
| United States | 39 | 2022 | 69872 | 0.310 |
Why?
|
| Cyclosporine | 9 | 2004 | 786 | 0.310 |
Why?
|
| Antilymphocyte Serum | 12 | 2003 | 492 | 0.310 |
Why?
|
| Histocompatibility | 2 | 2006 | 330 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 27 | 1998 | 9274 | 0.300 |
Why?
|
| Biopsy | 11 | 2014 | 6756 | 0.290 |
Why?
|
| Financing, Organized | 1 | 2008 | 202 | 0.290 |
Why?
|
| Fees and Charges | 2 | 2006 | 195 | 0.280 |
Why?
|
| Marketing | 1 | 2008 | 212 | 0.270 |
Why?
|
| Turkey | 3 | 2013 | 237 | 0.270 |
Why?
|
| Europe | 4 | 2021 | 3339 | 0.260 |
Why?
|
| Resource Allocation | 4 | 2007 | 341 | 0.260 |
Why?
|
| Critical Care | 1 | 2018 | 2647 | 0.260 |
Why?
|
| Compensation and Redress | 2 | 2016 | 71 | 0.250 |
Why?
|
| Bone Marrow Transplantation | 5 | 2019 | 2765 | 0.250 |
Why?
|
| Health Personnel | 1 | 2018 | 3218 | 0.240 |
Why?
|
| Developing Countries | 2 | 2014 | 2815 | 0.240 |
Why?
|
| Cyclosporins | 8 | 1991 | 220 | 0.230 |
Why?
|
| Antibodies | 6 | 2004 | 2460 | 0.230 |
Why?
|
| Prisoners | 3 | 2014 | 297 | 0.220 |
Why?
|
| Commodification | 1 | 2002 | 3 | 0.210 |
Why?
|
| Perfusion | 3 | 2023 | 1360 | 0.210 |
Why?
|
| Fund Raising | 1 | 2002 | 47 | 0.210 |
Why?
|
| Minors | 1 | 2002 | 50 | 0.210 |
Why?
|
| Social Class | 3 | 2015 | 1999 | 0.200 |
Why?
|
| Organizational Objectives | 3 | 2015 | 438 | 0.200 |
Why?
|
| Health Care Rationing | 4 | 2004 | 437 | 0.200 |
Why?
|
| Congresses as Topic | 3 | 2011 | 764 | 0.200 |
Why?
|
| Lung Transplantation | 5 | 2012 | 1153 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 3022 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 3158 | 0.190 |
Why?
|
| Hepatitis B | 3 | 2001 | 695 | 0.190 |
Why?
|
| Bioethics | 1 | 2002 | 116 | 0.190 |
Why?
|
| Patients | 2 | 2007 | 900 | 0.190 |
Why?
|
| Public Opinion | 4 | 2016 | 477 | 0.190 |
Why?
|
| Crime | 2 | 2013 | 215 | 0.180 |
Why?
|
| Swine | 3 | 2020 | 5917 | 0.180 |
Why?
|
| Tissue Banks | 1 | 2000 | 184 | 0.180 |
Why?
|
| Fungemia | 1 | 1999 | 53 | 0.180 |
Why?
|
| Intestines | 5 | 2012 | 1924 | 0.180 |
Why?
|
| Public Policy | 1 | 2004 | 572 | 0.170 |
Why?
|
| Adult | 80 | 2022 | 214055 | 0.170 |
Why?
|
| Iran | 2 | 2013 | 708 | 0.170 |
Why?
|
| Blood Substitutes | 1 | 2019 | 58 | 0.170 |
Why?
|
| Hypoxia, Brain | 1 | 1999 | 133 | 0.170 |
Why?
|
| Patient Rights | 2 | 2010 | 126 | 0.170 |
Why?
|
| Organ Preservation Solutions | 1 | 2019 | 98 | 0.160 |
Why?
|
| Renal Dialysis | 6 | 2016 | 1786 | 0.160 |
Why?
|
| Conflict of Interest | 2 | 2016 | 544 | 0.160 |
Why?
|
| Antibody Formation | 8 | 2002 | 1402 | 0.160 |
Why?
|
| Blood Group Incompatibility | 3 | 2008 | 146 | 0.160 |
Why?
|
| Canada | 5 | 2016 | 2065 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2017 | 5319 | 0.160 |
Why?
|
| Plasma Exchange | 1 | 1998 | 152 | 0.160 |
Why?
|
| Health Care Costs | 4 | 2015 | 3209 | 0.160 |
Why?
|
| Hepatitis B virus | 1 | 2001 | 513 | 0.150 |
Why?
|
| Complement C4b | 4 | 2005 | 135 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2006 | 1541 | 0.150 |
Why?
|
| Immune Tolerance | 7 | 2019 | 2258 | 0.150 |
Why?
|
| Internationality | 3 | 2012 | 1003 | 0.150 |
Why?
|
| Treatment Outcome | 20 | 2022 | 63114 | 0.150 |
Why?
|
| Time Factors | 22 | 2016 | 40075 | 0.150 |
Why?
|
| Age Factors | 11 | 2015 | 18370 | 0.140 |
Why?
|
| Patient Care | 1 | 2022 | 640 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2013 | 1534 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2002 | 895 | 0.140 |
Why?
|
| Hospitals, General | 1 | 2001 | 749 | 0.140 |
Why?
|
| Consensus | 3 | 2021 | 2959 | 0.140 |
Why?
|
| Professional Misconduct | 1 | 2016 | 73 | 0.140 |
Why?
|
| ABO Blood-Group System | 3 | 2008 | 367 | 0.140 |
Why?
|
| Drug Users | 1 | 2017 | 134 | 0.130 |
Why?
|
| Azathioprine | 8 | 2001 | 353 | 0.130 |
Why?
|
| Software | 2 | 2008 | 4443 | 0.130 |
Why?
|
| Central America | 1 | 2015 | 68 | 0.130 |
Why?
|
| Multiple Myeloma | 5 | 2019 | 5181 | 0.130 |
Why?
|
| Hepatitis C | 6 | 2003 | 1591 | 0.120 |
Why?
|
| Virus Diseases | 1 | 2000 | 711 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 4262 | 0.120 |
Why?
|
| Communicable Diseases | 2 | 2005 | 880 | 0.120 |
Why?
|
| Middle Aged | 58 | 2019 | 213383 | 0.120 |
Why?
|
| Risk Assessment | 8 | 2019 | 23338 | 0.120 |
Why?
|
| Male | 67 | 2019 | 350118 | 0.120 |
Why?
|
| Qatar | 1 | 2013 | 36 | 0.120 |
Why?
|
| Philippines | 1 | 2013 | 86 | 0.110 |
Why?
|
| Egypt | 1 | 2013 | 100 | 0.110 |
Why?
|
| Cardiovascular System | 1 | 2021 | 832 | 0.110 |
Why?
|
| Cultural Characteristics | 1 | 2015 | 262 | 0.110 |
Why?
|
| Risk | 7 | 2018 | 9687 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2019 | 1534 | 0.110 |
Why?
|
| Macaca fascicularis | 10 | 1998 | 915 | 0.110 |
Why?
|
| Bacteremia | 1 | 1999 | 962 | 0.110 |
Why?
|
| Colombia | 1 | 2013 | 258 | 0.110 |
Why?
|
| Capital Punishment | 1 | 2012 | 31 | 0.110 |
Why?
|
| Social Justice | 2 | 2015 | 456 | 0.110 |
Why?
|
| Policy | 1 | 2016 | 508 | 0.110 |
Why?
|
| Pakistan | 1 | 2013 | 295 | 0.110 |
Why?
|
| Female | 62 | 2019 | 380194 | 0.110 |
Why?
|
| Reperfusion Injury | 1 | 2019 | 1026 | 0.110 |
Why?
|
| Coercion | 1 | 2012 | 63 | 0.100 |
Why?
|
| Postoperative Complications | 14 | 2017 | 15295 | 0.100 |
Why?
|
| Truth Disclosure | 1 | 2016 | 436 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 3 | 1993 | 1602 | 0.100 |
Why?
|
| Risk Factors | 13 | 2019 | 72290 | 0.100 |
Why?
|
| Minority Groups | 1 | 1999 | 1223 | 0.100 |
Why?
|
| Disease Transmission, Infectious | 2 | 2009 | 547 | 0.100 |
Why?
|
| Ethics Committees, Clinical | 1 | 2012 | 56 | 0.100 |
Why?
|
| Muromonab-CD3 | 4 | 1999 | 96 | 0.100 |
Why?
|
| Physician-Patient Relations | 2 | 2015 | 3229 | 0.100 |
Why?
|
| Burns | 2 | 1999 | 1815 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2005 | 2788 | 0.100 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1993 | 573 | 0.100 |
Why?
|
| Africa South of the Sahara | 1 | 2014 | 724 | 0.100 |
Why?
|
| Malpractice | 1 | 2016 | 572 | 0.100 |
Why?
|
| Steroids | 6 | 2003 | 930 | 0.100 |
Why?
|
| Program Development | 2 | 2015 | 1316 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 1049 | 0.090 |
Why?
|
| Adolescent | 25 | 2016 | 85781 | 0.090 |
Why?
|
| Child | 23 | 2015 | 77709 | 0.090 |
Why?
|
| Postoperative Care | 3 | 2003 | 1486 | 0.090 |
Why?
|
| T-Lymphocytes | 18 | 2004 | 10180 | 0.090 |
Why?
|
| Brain | 3 | 2023 | 26385 | 0.090 |
Why?
|
| Taiwan | 1 | 2011 | 496 | 0.090 |
Why?
|
| Isoantibodies | 3 | 2005 | 679 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 7 | 2000 | 820 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2008 | 10252 | 0.090 |
Why?
|
| Hepatitis B Core Antigens | 2 | 2001 | 92 | 0.090 |
Why?
|
| Patient Transfer | 1 | 2016 | 761 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 2001 | 305 | 0.090 |
Why?
|
| Physician's Role | 1 | 2016 | 943 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2013 | 3743 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 3 | 1990 | 349 | 0.080 |
Why?
|
| Organizational Policy | 1 | 2011 | 429 | 0.080 |
Why?
|
| Lymphocele | 1 | 2008 | 16 | 0.080 |
Why?
|
| Schistosomiasis mansoni | 1 | 2009 | 85 | 0.080 |
Why?
|
| Psychometrics | 1 | 2018 | 3002 | 0.080 |
Why?
|
| Cecum | 1 | 2009 | 237 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 15076 | 0.080 |
Why?
|
| Transplantation Immunology | 4 | 1989 | 546 | 0.080 |
Why?
|
| Renal Insufficiency | 2 | 2013 | 804 | 0.080 |
Why?
|
| Regional Health Planning | 1 | 2008 | 97 | 0.080 |
Why?
|
| Retrospective Studies | 20 | 2022 | 77449 | 0.080 |
Why?
|
| Cell Transplantation | 1 | 2010 | 477 | 0.080 |
Why?
|
| Schistosoma mansoni | 1 | 2009 | 149 | 0.080 |
Why?
|
| Child, Preschool | 12 | 2015 | 41006 | 0.080 |
Why?
|
| Family | 3 | 2016 | 3147 | 0.080 |
Why?
|
| Communicable Disease Control | 2 | 2005 | 857 | 0.080 |
Why?
|
| Follow-Up Studies | 14 | 2019 | 39050 | 0.080 |
Why?
|
| Polytetrafluoroethylene | 1 | 2008 | 233 | 0.080 |
Why?
|
| Hospital Administration | 1 | 2011 | 353 | 0.080 |
Why?
|
| Portugal | 1 | 2007 | 87 | 0.080 |
Why?
|
| Animals | 24 | 2020 | 168757 | 0.070 |
Why?
|
| Nucleic Acids | 1 | 2010 | 182 | 0.070 |
Why?
|
| Parathyroid Glands | 2 | 1991 | 509 | 0.070 |
Why?
|
| Annual Reports as Topic | 1 | 2007 | 33 | 0.070 |
Why?
|
| Oxygen | 1 | 2019 | 4189 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 906 | 0.070 |
Why?
|
| India | 1 | 2013 | 2197 | 0.070 |
Why?
|
| Antibody Specificity | 4 | 2005 | 1095 | 0.070 |
Why?
|
| Cause of Death | 5 | 2017 | 3584 | 0.070 |
Why?
|
| Research Design | 2 | 2015 | 5987 | 0.070 |
Why?
|
| HLA-DR Antigens | 1 | 2008 | 645 | 0.070 |
Why?
|
| Immunoglobulin G | 5 | 2001 | 4560 | 0.070 |
Why?
|
| Surgery, Plastic | 1 | 2013 | 624 | 0.070 |
Why?
|
| Polycythemia | 1 | 2007 | 126 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2014 | 9849 | 0.070 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2004 | 745 | 0.070 |
Why?
|
| Human Rights | 1 | 2008 | 307 | 0.070 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2006 | 132 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2010 | 1405 | 0.070 |
Why?
|
| Forecasting | 1 | 2015 | 2951 | 0.070 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2006 | 168 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2017 | 1901 | 0.060 |
Why?
|
| Massachusetts | 2 | 2013 | 8663 | 0.060 |
Why?
|
| United Nations | 1 | 2006 | 165 | 0.060 |
Why?
|
| Complement C4 | 3 | 2002 | 257 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2008 | 549 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2013 | 2740 | 0.060 |
Why?
|
| Transplantation Chimera | 3 | 2019 | 612 | 0.060 |
Why?
|
| Databases as Topic | 2 | 2003 | 475 | 0.060 |
Why?
|
| Cross-Cultural Comparison | 1 | 2008 | 651 | 0.060 |
Why?
|
| Information Services | 1 | 2006 | 244 | 0.060 |
Why?
|
| Quality of Life | 3 | 2021 | 12804 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2007 | 497 | 0.060 |
Why?
|
| Diabetic Nephropathies | 4 | 2004 | 984 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2006 | 2250 | 0.060 |
Why?
|
| Critical Pathways | 2 | 2011 | 476 | 0.060 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 1984 | 126 | 0.060 |
Why?
|
| Lymphatic Vessels | 1 | 2008 | 353 | 0.060 |
Why?
|
| Acute Disease | 7 | 2003 | 7149 | 0.060 |
Why?
|
| Plasmapheresis | 1 | 2004 | 211 | 0.060 |
Why?
|
| Clinical Trials as Topic | 8 | 2010 | 7913 | 0.060 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2008 | 933 | 0.060 |
Why?
|
| Eligibility Determination | 1 | 2007 | 403 | 0.060 |
Why?
|
| Tissue Survival | 2 | 2019 | 118 | 0.060 |
Why?
|
| Bone Diseases | 1 | 2007 | 416 | 0.060 |
Why?
|
| Fatal Outcome | 3 | 2009 | 1850 | 0.060 |
Why?
|
| Philadelphia | 1 | 2003 | 266 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 2017 | 2065 | 0.050 |
Why?
|
| Virginia | 1 | 2002 | 121 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 19905 | 0.050 |
Why?
|
| Liver Failure | 1 | 2004 | 241 | 0.050 |
Why?
|
| Communications Media | 1 | 2002 | 43 | 0.050 |
Why?
|
| Spain | 1 | 2003 | 465 | 0.050 |
Why?
|
| Mycoses | 2 | 1999 | 376 | 0.050 |
Why?
|
| Catholicism | 1 | 2002 | 30 | 0.050 |
Why?
|
| Boston | 6 | 2002 | 9313 | 0.050 |
Why?
|
| Lymphopoiesis | 1 | 2002 | 135 | 0.050 |
Why?
|
| Skin Transplantation | 4 | 1984 | 1074 | 0.050 |
Why?
|
| Neoplasms | 2 | 2001 | 21683 | 0.050 |
Why?
|
| Resuscitation | 2 | 2003 | 658 | 0.050 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 482 | 0.050 |
Why?
|
| Prednisone | 4 | 1994 | 1574 | 0.050 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2002 | 170 | 0.050 |
Why?
|
| Heart Transplantation | 3 | 2003 | 3110 | 0.050 |
Why?
|
| Judgment | 1 | 2003 | 281 | 0.050 |
Why?
|
| Patient Advocacy | 1 | 2003 | 353 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2016 | 3749 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 3 | 1996 | 523 | 0.050 |
Why?
|
| B-Lymphocytes | 3 | 2004 | 4665 | 0.050 |
Why?
|
| Poverty | 2 | 2004 | 2660 | 0.050 |
Why?
|
| Blood Transfusion | 4 | 1999 | 1301 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2004 | 881 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 12354 | 0.050 |
Why?
|
| Insurance | 1 | 2002 | 111 | 0.050 |
Why?
|
| Infant | 5 | 2015 | 35136 | 0.050 |
Why?
|
| Tuberculosis | 2 | 2012 | 1912 | 0.050 |
Why?
|
| Drug Therapy, Combination | 6 | 2001 | 6489 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 5 | 2002 | 1681 | 0.050 |
Why?
|
| Kidney Glomerulus | 3 | 1998 | 697 | 0.050 |
Why?
|
| Twins, Monozygotic | 1 | 2002 | 458 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 3 | 2008 | 5391 | 0.050 |
Why?
|
| Algorithms | 4 | 2013 | 13881 | 0.040 |
Why?
|
| Heparin | 1 | 2007 | 1637 | 0.040 |
Why?
|
| Carboxyhemoglobin | 1 | 1999 | 81 | 0.040 |
Why?
|
| Accidents, Home | 1 | 1999 | 75 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2004 | 652 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1989 | 2540 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2003 | 767 | 0.040 |
Why?
|
| Personal Autonomy | 1 | 2002 | 298 | 0.040 |
Why?
|
| Methylprednisolone | 4 | 2003 | 387 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1999 | 62 | 0.040 |
Why?
|
| Complement C3b | 1 | 1999 | 106 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 1998 | 3336 | 0.040 |
Why?
|
| Hormones | 1 | 2003 | 889 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1999 | 112 | 0.040 |
Why?
|
| Logistic Models | 1 | 2014 | 13408 | 0.040 |
Why?
|
| Extracorporeal Circulation | 1 | 2019 | 182 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2005 | 2382 | 0.040 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 1998 | 19 | 0.040 |
Why?
|
| Infection Control | 2 | 2011 | 966 | 0.040 |
Why?
|
| Immunization | 4 | 2001 | 1256 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2014 | 4371 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 3870 | 0.040 |
Why?
|
| HTLV-I Infections | 1 | 1998 | 101 | 0.040 |
Why?
|
| Renal Artery | 2 | 1999 | 398 | 0.040 |
Why?
|
| Toxoplasmosis | 1 | 1998 | 91 | 0.040 |
Why?
|
| Anemia | 1 | 2007 | 1506 | 0.040 |
Why?
|
| Transplantation Conditioning | 2 | 2019 | 1598 | 0.040 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1977 | 66 | 0.040 |
Why?
|
| Emotions | 1 | 2009 | 2661 | 0.040 |
Why?
|
| Creatinine | 8 | 1996 | 1919 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 2085 | 0.040 |
Why?
|
| Aged | 16 | 2019 | 163280 | 0.040 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1996 | 49 | 0.040 |
Why?
|
| Haplorhini | 2 | 1996 | 552 | 0.040 |
Why?
|
| Reoperation | 4 | 1996 | 4201 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2015 | 25625 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 3 | 1998 | 3772 | 0.040 |
Why?
|
| Prospective Studies | 8 | 2012 | 53288 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2002 | 1462 | 0.030 |
Why?
|
| Transplantation Tolerance | 1 | 2001 | 617 | 0.030 |
Why?
|
| Chimera | 2 | 1999 | 485 | 0.030 |
Why?
|
| Decision Making | 1 | 2010 | 3887 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2002 | 687 | 0.030 |
Why?
|
| Peptide Fragments | 4 | 2005 | 5097 | 0.030 |
Why?
|
| Serologic Tests | 1 | 1998 | 374 | 0.030 |
Why?
|
| Pancreas | 1 | 2002 | 1686 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2006 | 6196 | 0.030 |
Why?
|
| Communication | 2 | 2016 | 3749 | 0.030 |
Why?
|
| Drug Resistance | 3 | 2001 | 1609 | 0.030 |
Why?
|
| Syphilis | 1 | 1998 | 227 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2001 | 1200 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 7785 | 0.030 |
Why?
|
| Models, Statistical | 3 | 2006 | 5102 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2012 | 40561 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 1998 | 357 | 0.030 |
Why?
|
| Leukocyte Count | 4 | 1994 | 1588 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 1993 | 1155 | 0.030 |
Why?
|
| Hyperparathyroidism | 1 | 1976 | 339 | 0.030 |
Why?
|
| Lymphocyte Depletion | 2 | 1994 | 608 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 1956 | 0.030 |
Why?
|
| Kidney Pelvis | 2 | 1987 | 188 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 240 | 0.030 |
Why?
|
| Horses | 2 | 1984 | 304 | 0.030 |
Why?
|
| Laparoscopy | 2 | 2008 | 2151 | 0.030 |
Why?
|
| Diabetes Mellitus | 3 | 2004 | 5751 | 0.030 |
Why?
|
| Random Allocation | 3 | 1987 | 2429 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1977 | 2031 | 0.030 |
Why?
|
| Ureter | 2 | 1987 | 375 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 1869 | 0.030 |
Why?
|
| Attitude to Death | 1 | 2015 | 382 | 0.030 |
Why?
|
| Chronic Disease | 4 | 2005 | 9146 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 1999 | 980 | 0.030 |
Why?
|
| Vasopressins | 2 | 2003 | 370 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 1993 | 455 | 0.020 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2011 | 93 | 0.020 |
Why?
|
| Skin Neoplasms | 2 | 2001 | 5686 | 0.020 |
Why?
|
| Triiodothyronine | 2 | 2003 | 494 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1993 | 841 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1999 | 1401 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2003 | 12245 | 0.020 |
Why?
|
| Rosette Formation | 4 | 1984 | 153 | 0.020 |
Why?
|
| Federal Government | 1 | 1992 | 260 | 0.020 |
Why?
|
| Life Support Care | 1 | 1992 | 228 | 0.020 |
Why?
|
| Health Planning | 1 | 1992 | 238 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 1992 | 315 | 0.020 |
Why?
|
| Erythrocytes | 2 | 2019 | 2455 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2003 | 2987 | 0.020 |
Why?
|
| Length of Stay | 4 | 2003 | 6309 | 0.020 |
Why?
|
| Drug Administration Schedule | 3 | 1987 | 4933 | 0.020 |
Why?
|
| Heart | 1 | 2003 | 4467 | 0.020 |
Why?
|
| Hypocalcemia | 2 | 1984 | 191 | 0.020 |
Why?
|
| Coma | 2 | 2009 | 475 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 1239 | 0.020 |
Why?
|
| Fluconazole | 1 | 1989 | 146 | 0.020 |
Why?
|
| Thyroxine | 2 | 2003 | 667 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2001 | 4420 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2019 | 2948 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 2006 | 2645 | 0.020 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1989 | 201 | 0.020 |
Why?
|
| Patient Admission | 1 | 2016 | 1380 | 0.020 |
Why?
|
| Urinary Tract Infections | 2 | 1992 | 788 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1999 | 4199 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2009 | 182 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 2004 | 15165 | 0.020 |
Why?
|
| Religion and Medicine | 1 | 2009 | 163 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 1999 | 1917 | 0.020 |
Why?
|
| Lithotripsy, Laser | 1 | 1988 | 46 | 0.020 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1988 | 138 | 0.020 |
Why?
|
| Incidence | 5 | 2012 | 20947 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2004 | 1842 | 0.020 |
Why?
|
| Italy | 1 | 2009 | 832 | 0.020 |
Why?
|
| Survival Rate | 4 | 1999 | 12788 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 1992 | 732 | 0.020 |
Why?
|
| Acute Kidney Injury | 2 | 1977 | 1972 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1999 | 1475 | 0.020 |
Why?
|
| Lithotripsy | 1 | 1988 | 143 | 0.020 |
Why?
|
| Morals | 1 | 2009 | 284 | 0.020 |
Why?
|
| Nucleoside Deaminases | 1 | 1986 | 58 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 1209 | 0.020 |
Why?
|
| Aging | 2 | 2002 | 8664 | 0.020 |
Why?
|
| Arenaviridae Infections | 1 | 2006 | 51 | 0.020 |
Why?
|
| Duodenum | 1 | 1989 | 483 | 0.020 |
Why?
|
| Mice | 6 | 1996 | 81183 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 455 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2002 | 2505 | 0.020 |
Why?
|
| Hepatectomy | 1 | 1989 | 550 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2008 | 886 | 0.020 |
Why?
|
| Health Education | 1 | 2012 | 1056 | 0.020 |
Why?
|
| Sutures | 1 | 1987 | 299 | 0.020 |
Why?
|
| Gallstones | 1 | 1988 | 286 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2016 | 2569 | 0.020 |
Why?
|
| Psychology | 1 | 2007 | 356 | 0.020 |
Why?
|
| Zoonoses | 1 | 2006 | 185 | 0.020 |
Why?
|
| Lymphoma | 2 | 1995 | 1877 | 0.020 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 1985 | 80 | 0.020 |
Why?
|
| Hemophilia A | 1 | 1988 | 351 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2019 | 19229 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2016 | 2063 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 1993 | 5974 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 1989 | 804 | 0.020 |
Why?
|
| Recurrence | 2 | 1988 | 8340 | 0.020 |
Why?
|
| Methods | 1 | 1984 | 1129 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1990 | 1681 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2012 | 1320 | 0.010 |
Why?
|
| Hypertension | 4 | 2004 | 8480 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 1986 | 241 | 0.010 |
Why?
|
| Schools | 1 | 2012 | 1433 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 2007 | 812 | 0.010 |
Why?
|
| Renal Agents | 1 | 2003 | 32 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2016 | 3313 | 0.010 |
Why?
|
| Prednisolone | 1 | 2004 | 334 | 0.010 |
Why?
|
| Angiography | 1 | 1988 | 1639 | 0.010 |
Why?
|
| Liver | 3 | 2008 | 7474 | 0.010 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 522 | 0.010 |
Why?
|
| Interferon Type I | 2 | 1983 | 542 | 0.010 |
Why?
|
| Drainage | 1 | 2008 | 1142 | 0.010 |
Why?
|
| Cricetinae | 1 | 2006 | 2472 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2004 | 684 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 1976 | 2861 | 0.010 |
Why?
|
| Primates | 1 | 1984 | 545 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1983 | 277 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 7181 | 0.010 |
Why?
|
| Leukemia | 1 | 1989 | 1511 | 0.010 |
Why?
|
| Organization and Administration | 1 | 1981 | 52 | 0.010 |
Why?
|
| Biological Dressings | 1 | 1981 | 30 | 0.010 |
Why?
|
| Spouses | 1 | 2004 | 286 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1983 | 986 | 0.010 |
Why?
|
| Homocysteine | 1 | 2004 | 647 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14722 | 0.010 |
Why?
|
| Ribavirin | 1 | 2003 | 395 | 0.010 |
Why?
|
| Laser Therapy | 1 | 1988 | 1072 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 894 | 0.010 |
Why?
|
| Health Behavior | 1 | 2012 | 2636 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1992 | 3176 | 0.010 |
Why?
|
| Blood Pressure | 3 | 2004 | 8554 | 0.010 |
Why?
|
| Mental Health | 2 | 2007 | 3019 | 0.010 |
Why?
|
| Cholesterol | 2 | 2004 | 2917 | 0.010 |
Why?
|
| Patient Readmission | 1 | 1994 | 3114 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1987 | 3913 | 0.010 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 1999 | 7 | 0.010 |
Why?
|
| Pseudomonas Infections | 1 | 1984 | 613 | 0.010 |
Why?
|
| Siblings | 1 | 2004 | 854 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 2278 | 0.010 |
Why?
|
| Hospitals, Psychiatric | 1 | 1981 | 332 | 0.010 |
Why?
|
| Monitoring, Physiologic | 2 | 1984 | 1738 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2009 | 1470 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 12959 | 0.010 |
Why?
|
| Blood Preservation | 1 | 1999 | 177 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1984 | 1375 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2010 | 2025 | 0.010 |
Why?
|
| Uric Acid | 1 | 2004 | 766 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2003 | 895 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 110 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 2001 | 1607 | 0.010 |
Why?
|
| Mortality | 2 | 2002 | 2864 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2011 | 6442 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1998 | 158 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1998 | 370 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1990 | 10943 | 0.010 |
Why?
|
| Calcium | 1 | 1991 | 5756 | 0.010 |
Why?
|
| Suture Techniques | 1 | 1982 | 798 | 0.010 |
Why?
|
| Organizational Innovation | 1 | 1981 | 559 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 1977 | 235 | 0.010 |
Why?
|
| Technetium | 1 | 1977 | 334 | 0.010 |
Why?
|
| Complement Activation | 1 | 1999 | 453 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 6538 | 0.010 |
Why?
|
| Immune Sera | 1 | 1977 | 641 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1999 | 626 | 0.010 |
Why?
|
| Tetany | 1 | 1976 | 12 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 1990 | 9959 | 0.010 |
Why?
|
| Constriction | 1 | 1996 | 181 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1983 | 1821 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 378 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1992 | 4253 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1977 | 471 | 0.010 |
Why?
|
| Coronary Disease | 2 | 2004 | 6077 | 0.010 |
Why?
|
| Pyelonephritis | 1 | 1975 | 75 | 0.010 |
Why?
|
| Liver Diseases | 2 | 1999 | 1253 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1996 | 309 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 1983 | 2988 | 0.010 |
Why?
|
| Monkey Diseases | 1 | 1975 | 77 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2004 | 2356 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1286 | 0.010 |
Why?
|
| Medicare | 1 | 1992 | 6566 | 0.010 |
Why?
|
| Demography | 1 | 1999 | 1656 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1994 | 349 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 2107 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1995 | 316 | 0.010 |
Why?
|
| Macaca | 1 | 1975 | 440 | 0.010 |
Why?
|
| Glomerulonephritis | 1 | 1975 | 372 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1999 | 1366 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1976 | 732 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2001 | 2007 | 0.010 |
Why?
|
| Monitoring, Immunologic | 1 | 1993 | 100 | 0.010 |
Why?
|
| Pentamidine | 1 | 1992 | 45 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1996 | 440 | 0.010 |
Why?
|
| Legislation, Medical | 1 | 1973 | 100 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1986 | 5021 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 3778 | 0.010 |
Why?
|
| Adenoma, Bile Duct | 1 | 1992 | 30 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 3610 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 3508 | 0.010 |
Why?
|
| Brain Damage, Chronic | 1 | 1973 | 265 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1984 | 3461 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 2559 | 0.010 |
Why?
|
| HIV Infections | 1 | 1998 | 16718 | 0.010 |
Why?
|
| Immunoradiometric Assay | 1 | 1991 | 24 | 0.010 |
Why?
|
| Survival | 1 | 1992 | 163 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 1996 | 565 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1992 | 249 | 0.010 |
Why?
|
| Blood Glucose | 3 | 1988 | 6256 | 0.010 |
Why?
|
| Antigens, Surface | 2 | 1987 | 1663 | 0.010 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1976 | 582 | 0.010 |
Why?
|
| Isoantigens | 2 | 1987 | 567 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 4328 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2002 | 2957 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 1998 | 2170 | 0.010 |
Why?
|
| Parents | 1 | 2004 | 3407 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 56430 | 0.010 |
Why?
|
| Aerosols | 1 | 1992 | 625 | 0.010 |
Why?
|
| Freezing | 2 | 1982 | 303 | 0.010 |
Why?
|
| Contrast Media | 1 | 1983 | 5300 | 0.010 |
Why?
|
| Wound Healing | 1 | 1981 | 2785 | 0.010 |
Why?
|
| Lymph Nodes | 2 | 1998 | 3474 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 1989 | 119 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1991 | 482 | 0.010 |
Why?
|
| Candida | 1 | 1989 | 172 | 0.010 |
Why?
|
| Double-Blind Method | 3 | 1992 | 12026 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1975 | 2375 | 0.000 |
Why?
|
| Diabetes Complications | 1 | 1975 | 1359 | 0.000 |
Why?
|
| Common Bile Duct | 1 | 1988 | 109 | 0.000 |
Why?
|
| Heart Rate | 1 | 1999 | 4091 | 0.000 |
Why?
|
| Lung | 1 | 2006 | 9856 | 0.000 |
Why?
|
| Health Status | 1 | 2000 | 4034 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1995 | 4740 | 0.000 |
Why?
|
| Ureteral Calculi | 1 | 1987 | 110 | 0.000 |
Why?
|
| Genotype | 1 | 2001 | 12951 | 0.000 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1986 | 91 | 0.000 |
Why?
|
| Factor VIII | 1 | 1988 | 347 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1990 | 2327 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1994 | 2617 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1991 | 2274 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 6171 | 0.000 |
Why?
|
| Disease Outbreaks | 1 | 1975 | 1772 | 0.000 |
Why?
|
| Respiratory Insufficiency | 1 | 1973 | 1199 | 0.000 |
Why?
|
| Parathyroid Hormone | 1 | 1991 | 1801 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 25043 | 0.000 |
Why?
|
| Kidney Tubules, Proximal | 1 | 1986 | 416 | 0.000 |
Why?
|
| Hepatitis B Vaccines | 1 | 1985 | 194 | 0.000 |
Why?
|
| Prognosis | 1 | 2004 | 29063 | 0.000 |
Why?
|
| Base Sequence | 1 | 1995 | 12797 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1987 | 389 | 0.000 |
Why?
|
| Lasers | 1 | 1988 | 952 | 0.000 |
Why?
|
| Triglycerides | 1 | 1991 | 2454 | 0.000 |
Why?
|
| Pulmonary Embolism | 1 | 1996 | 2376 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 15540 | 0.000 |
Why?
|
| Stroke Volume | 1 | 1996 | 5007 | 0.000 |
Why?
|
| Vascular Diseases | 1 | 1991 | 1161 | 0.000 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1982 | 329 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 18111 | 0.000 |
Why?
|
| Urography | 1 | 1983 | 313 | 0.000 |
Why?
|
| Hospital Bed Capacity, 100 to 299 | 1 | 1981 | 11 | 0.000 |
Why?
|
| Sepsis | 1 | 1975 | 2593 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1994 | 4386 | 0.000 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 1984 | 277 | 0.000 |
Why?
|
| Rats | 1 | 1977 | 24260 | 0.000 |
Why?
|
| Rhode Island | 1 | 1981 | 347 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 57776 | 0.000 |
Why?
|
| Stroke | 1 | 2002 | 9981 | 0.000 |
Why?
|
| Students, Medical | 1 | 1973 | 1862 | 0.000 |
Why?
|
| Cytological Techniques | 1 | 1981 | 219 | 0.000 |
Why?
|
| Herpes Simplex | 1 | 1983 | 470 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1992 | 2214 | 0.000 |
Why?
|
| Pregnancy | 2 | 1982 | 29144 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1986 | 2263 | 0.000 |
Why?
|
| Lymphotoxin-alpha | 1 | 1978 | 96 | 0.000 |
Why?
|
| Bone Density | 1 | 1991 | 3468 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1988 | 5078 | 0.000 |
Why?
|
| Endothelium, Vascular | 1 | 1990 | 4456 | 0.000 |
Why?
|
| Herpesvirus 4, Human | 1 | 1983 | 1041 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1973 | 6150 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1977 | 484 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1975 | 6600 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1988 | 8324 | 0.000 |
Why?
|
| Physicians | 1 | 1973 | 4567 | 0.000 |
Why?
|
| Tuberculin Test | 1 | 1975 | 214 | 0.000 |
Why?
|
| Spleen | 1 | 1975 | 2362 | 0.000 |
Why?
|
| Insulin | 1 | 1977 | 6580 | 0.000 |
Why?
|